Literature DB >> 31613957

Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency.

Riccardo Pofi1,2, Alessandro Prete3, Vivien Thornton-Jones1, Jillian Bryce4, Salma R Ali4, S Faisal Ahmed4, Antonio Balsamo5, Federico Baronio5, Amalia Cannuccia6, Ayla Guven7, Tulay Guran8, Feyza Darendeliler9, Claire Higham10, Walter Bonfig11, Liat de Vries12,13, Tania A S S Bachega14, Mirela C Miranda14, Berenice B Mendonca14, Violeta Iotova15, Màrta Korbonits16, Nils P Krone17, Ruth Krone18, Andrea Lenzi2, Wiebke Arlt3,19, Richard J Ross17, Andrea M Isidori2, Jeremy W Tomlinson1.   

Abstract

CONTEXT: No consensus exists for optimization of mineralocorticoid therapy in patients with primary adrenal insufficiency.
OBJECTIVE: To explore the relationship between mineralocorticoid (MC) replacement dose, plasma renin concentration (PRC), and clinically important variables to determine which are most helpful in guiding MC dose titration in primary adrenal insufficiency.
DESIGN: Observational, retrospective, longitudinal analysis. PATIENTS: A total of 280 patients (with 984 clinical visits and plasma renin measurements) with primary adrenal insufficiency were recruited from local databases and the international congenital adrenal hyperplasia (CAH) registry (www.i-cah.org). Thirty-seven patients were excluded from the final analysis due to incomplete assessment. Data from 204 patients with salt-wasting CAH (149 adults and 55 children) and 39 adult patients with Addison disease (AD) were analysed. MAIN OUTCOME MEASURES: PRC, electrolytes, blood pressure (BP), and anthropometric parameters were used to predict their utility in optimizing MC replacement dose.
RESULTS: PRC was low, normal, or high in 19%, 36%, and 44% of patients, respectively, with wide variability in MC dose and PRC. Univariate analysis demonstrated a direct positive relationship between MC dose and PRC in adults and children. There was no relationship between MC dose and BP in adults, while BP increased with increasing MC dose in children. Using multiple regression modeling, sodium was the only measurement that predicted PRC in adults. Longitudinally, the change in MC dose was able to predict potassium, but not BP or PRC.
CONCLUSIONS: The relationship between MC dose and PRC is complex and this may reflect variability in sampling with respect to posture, timing of last MC dose, adherence, and concomitant medications. Our data suggest that MC titration should not primarily be based only on PRC normalization, but also on clinical parameters such as BP and electrolyte concentration. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31613957     DOI: 10.1210/clinem/dgz055

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

2.  Characterization of patients with adrenal insufficiency and frequent adrenal crises.

Authors:  Marcus Quinkler; Robert D Murray; Pinggao Zhang; Claudio Marelli; Robert Petermann; Andrea M Isidori; Bertil Ekman
Journal:  Eur J Endocrinol       Date:  2021-05-04       Impact factor: 6.664

Review 3.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

4.  Treatment of congenital adrenal hyperplasia in children aged 0-3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure.

Authors:  Uta Neumann; Annelieke van der Linde; Ruth E Krone; Nils P Krone; Ayla Güven; Tülay Güran; Heba Elsedfy; Sukran Poyrazoglu; Feyza Darendeliler; Tania A S S Bachega; Antonio Balsamo; Sabine E Hannema; Niels Birkebaek; Ana Vieites; Ajay Thankamony; Martine Cools; Tatjana Milenkovic; Walter Bonfig; Eduardo Correa Costa; Navoda Atapattu; Liat de Vries; Guilherme Guaragna-Filho; Marta Korbonits; Klaus Mohnike; Jillian Bryce; S Faisal Ahmed; Bernard Voet; Oliver Blankenstein; Hedi L Claahsen-van der Grinten
Journal:  Eur J Endocrinol       Date:  2022-04-11       Impact factor: 6.558

5.  Health status of children and young persons with congenital adrenal hyperplasia in the UK (CAH-UK): a cross-sectional multi-centre study.

Authors:  Irina Bacila; Neil Richard Lawrence; Sundus Mahdi; Sabah Alvi; Timothy D Cheetham; Elizabeth Crowne; Urmi Das; Mehul Tulsidas Dattani; Justin H Davies; Evelien Gevers; Ruth E Krone; Andreas Kyriakou; Leena Patel; Tabitha Randell; Fiona J Ryan; Brian Keevil; S Faisal Ahmed; Nils P Krone
Journal:  Eur J Endocrinol       Date:  2022-09-16       Impact factor: 6.558

6.  Residual Corticosteroid Production in Autoimmune Addison Disease.

Authors:  Åse Bjorvatn Sævik; Anna-Karin Åkerman; Paal Methlie; Marcus Quinkler; Anders Palmstrøm Jørgensen; Charlotte Höybye; Aleksandra J Debowska; Bjørn Gunnar Nedrebø; Anne Lise Dahle; Siri Carlsen; Aneta Tomkowicz; Stina Therese Sollid; Ingrid Nermoen; Kaja Grønning; Per Dahlqvist; Guri Grimnes; Jakob Skov; Trine Finnes; Susanna F Valland; Jeanette Wahlberg; Synnøve Emblem Holte; Katerina Simunkova; Olle Kämpe; Eystein Sverre Husebye; Sophie Bensing; Marianne Øksnes
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.